Supernus to acquire depression drugmaker Sage

6 hours ago 1

Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the companies announced on Monday.
Shares of Supernus (NASDAQ:SUPN) traded marginally

Recommended For You